Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Alembic (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide Alembic, is an angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is combined with amlodipine and hydrochlorothiazide to treat hypertension in adult patients.

GNH USA supplies Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide Alembic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide is indicated for hypertension, acting on the renin‑angiotensin system and vascular smooth muscle.

- Essential hypertension: reduces systolic and diastolic blood pressure. - Hypertension with fluid retention: adds diuretic effect to improve control. - Hypertension requiring multiple mechanisms: provides combined ARB, calcium‑channel blockade, and diuresis for better efficacy.

Common Side Effects: - Dizziness - Headache - Peripheral edema - Flushing - Cough - Fatigue

Serious or Rare Side Effects: - Angioedema - Severe hypotension - Electrolyte imbalance (e.g., hyper‑ or hypokalemia) - Acute renal impairment - Hepatic dysfunction - Pancreatitis

Before initiating therapy, consider the following precautions: - Renal function: monitor serum creatinine and potassium levels. - Electrolytes: check for hypokalemia or hyperkalemia, especially with diuretic use. - Pregnancy: contraindicated in the second and third trimesters. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Concomitant drugs: avoid NSAIDs that may blunt antihypertensive effect. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide may interact with other medicines as follows:

Major Interactions (Avoid): - Potassium‑sparing diuretics: risk of hyperkalemia. - ACE inhibitors or aliskiren in diabetic patients: increased risk of renal dysfunction. - NSAIDs: may reduce antihypertensive efficacy. - Lithium: increased lithium toxicity. - Concomitant use with other ARBs: additive renal effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise amlodipine levels. - CYP3A4 inducers (e.g., rifampicin): may lower amlodipine exposure. - Antacids containing aluminum or magnesium: may affect absorption. - Beta‑blockers: additive hypotensive effect. - Antidiabetic agents: may require dose adjustment due to improved glycemic control.